- Home
- IKNA vs KPTI Comparison
IKNA vs KPTI Comparison
Compare IKNA & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- KPTI
- Stock Information
- Founded
- IKNA 2016
- KPTI 2008
- Country
- IKNA United States
- KPTI United States
- Employees
- IKNA N/A
- KPTI N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- IKNA Health Care
- KPTI Health Care
- Exchange
- IKNA Nasdaq
- KPTI Nasdaq
- Market Cap
- IKNA 61.8M
- KPTI 54.4M
- IPO Year
- IKNA 2021
- KPTI 2013
- Fundamental
- Price
- IKNA $1.13
- KPTI $6.01
- Analyst Decision
- IKNA Buy
- KPTI Strong Buy
- Analyst Count
- IKNA 2
- KPTI 5
- Target Price
- IKNA $3.00
- KPTI $61.00
- AVG Volume (30 Days)
- IKNA 96.4K
- KPTI 85.6K
- Earning Date
- IKNA 05-08-2025
- KPTI 05-20-2025
- Dividend Yield
- IKNA N/A
- KPTI N/A
- EPS Growth
- IKNA N/A
- KPTI N/A
- EPS
- IKNA N/A
- KPTI N/A
- Revenue
- IKNA N/A
- KPTI $145,237,000.00
- Revenue This Year
- IKNA N/A
- KPTI $4.87
- Revenue Next Year
- IKNA N/A
- KPTI $16.29
- P/E Ratio
- IKNA N/A
- KPTI N/A
- Revenue Growth
- IKNA N/A
- KPTI N/A
- 52 Week Low
- IKNA $0.97
- KPTI $3.51
- 52 Week High
- IKNA $1.94
- KPTI $18.00
- Technical
- Relative Strength Index (RSI)
- IKNA 43.57
- KPTI 51.12
- Support Level
- IKNA $1.22
- KPTI $5.52
- Resistance Level
- IKNA $1.29
- KPTI $7.90
- Average True Range (ATR)
- IKNA 0.09
- KPTI 0.69
- MACD
- IKNA -0.01
- KPTI 0.04
- Stochastic Oscillator
- IKNA 23.33
- KPTI 24.73
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.